Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

  • Almirall brings experience in privacy and pharmaceutical law, as well as in developing guidance, standards and recommendations for communicating clinical trial data to patients

  • The project will last four years and will involve 27 partners from 16 EU and extra-EU Member States, including patient organisations, hospitals, universities, SMEs and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA ).

BARCELONA, Spain, November 28, 2022–(BUSINESS WIRE)–Almirall, SA (ALM)a global biopharmaceutical company focused on skin health, today announced its participation in FACILITATE(FrAwork for VSIINicholasL trIon the day of the participantsBY reuse for full use Jtransparent and Eethical ecosystem) a patient-focused project of the Innovative Medicines Initiative (IMI) aimed at create a framework for access and reuse of clinical trial participant data for a fully compliant and ethical ecosystem. The primary goal of FACILITATE is to help return clinical trial data to study participants, ready for reuse in further research or healthcare practice, improving the current situation where data clinical trials are isolated in separate repositories and cannot be used outside of the clinical trial.

This press release is multimedia. View the full press release here:

Almirall headquarters in Barcelona (Photo: Business Wire)

Almirall’s main contribution focuses on providing expertise on privacy and pharmaceutical law issues, as well as developing guidelines, standards and recommendations for the return of clinical trial data to patients. . In addition, the company also provides expertise in specifying clinical trial use cases, stakeholder requirements, and developing tools for end users.

Facilitate is built on a data-driven, patient-centric technology platform with 27 partners from 17 EU and non-EU member states. Participants include patient associations, hospitals, universities, innovative small and medium-sized enterprises and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and with the Università degli Studi di Modena e Reggio Emilia as as project coordinator. The project, which was approved by the IMI Joint Undertaking (European Commission and EFPIA) in 2021, was launched this year with the FACILITATE site.

The launch of FACILITATE advances patient empowerment in clinical trials. At Almirall, we are delighted to contribute to this patient-focused IMI project with our strong experience in clinical trials and our commitment to ethics and transparency. This project is fully in line with our patient-centric strategy aimed at improving their quality of life,” declared Diego Herrera, head of the FACILITATE project at Almirall.

“FACILITATE is an IMI-JU project that builds on the collaborative efforts of many public and private partners and aims to manage the return of individual clinical trial data in a trusted legal and ethical environment. based on a patient’s needs, FACILITATE Aspiration is developing a prototype process that enables the feedback of clinical trial data during and after the clinical trial and enables the secondary use of that data”said Prof Johanna Blom, University of Modena-Reggio Emilia (UNIMORE) vice-coordinator of FACILITATE

The FACILITATE project has received funding from the Innovative Medicines Initiative 2 (JU) Joint Undertaking under Grant Agreement No 101034366. The Joint Undertaking is supported by the Horizon 2020 research and innovation program of the European Union and EFPIA.

For more information on FACILITATE, please visit

About Admirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to meet the needs of patients through science to improve their lives. Our Noble Purpose is at the heart of our work: “To transform the world of patients by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and revolutionary medical dermatology products to bring our innovative solutions to patients who need them.

The company, founded in 1943 and based in Barcelona, ​​is listed on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has always focused on patient needs. Currently, Almirall has a direct presence in 21 countries and strategic agreements in more than 70, with approximately 1,800 employees. The total turnover in 2021 was 836.5 million euros.

For more information, visit

Legal disclaimer

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to historical information, are “forward-looking statements”. These statements are based on currently available information and on the best estimates and assumptions that the Company considers to be reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those stated by these forward-looking statements. The Company expressly disclaims any obligation to revise or update any forward-looking statements, objectives or estimates contained herein to reflect any change in assumptions, events or circumstances on which such forward-looking statements are based, except if required by applicable law. .

See the source version on


Almirall media contact:
Laura Blazquez
Telephone: (+34) 600 430 581

Investor Relations Contact
Pablo Divasson del Fraile
Telephone: (+34) 93 291 3087

Contact person for corporate communication:
Mar Ramirez
Telephone: (+34) 659614173

#Almirall #joins #FACILITATE #patientfocused #Innovative #Medicines #Initiative #IMI #project #enable #clinical #trial #data #study #participants

Leave a Comment

Your email address will not be published. Required fields are marked *